| Business Summary | | CytRx
Corporation
is
engaged
in
the
development
and
commercialization
of
pharmaceutical
products.
The
Company's
current
research
and
development
activities
include
Flocor,
an
intravenous
agent
for
treatment
of
sickle
cell
disease
and
other
acute
vaso-occlusive
disorders;
and
TranzFect,
a
delivery
technology
for
DNA-based
vaccines.
The
Company
also
has
a
research
pipeline
with
opportunities
in
the
areas
of
muscular
dystrophy,
cancer,
spinal
cord
injury,
vaccine
delivery
and
gene
therapy. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CYTR
engages
in
the
development
of
pharmaceutical
products
to
treat
acute
sickle
cell
crisis
and
other
vascular
diseases
and
technologies
to
improve
effectiveness
of
vaccines.
For
the
six
months
ended
6/30/01,
revenues
fell
47%
to
$337
thousand.
Net
loss
from
continuing
operations
rose
40%
to
$2.4
million.
Results
reflect
lower
grant
income
and
the
effect
of
overall
slowdown
of
the
economy,
partially
offset
by
lower
research
and
development
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Raymond Carnahan, Jr., 75 Chairman | -- | Jack Luchese, 52 Pres,
CEO, Director | $368K | Mark Reynolds, 39 CFO,
VP-Fin., Sec. | 138K | William Fleck, 43 VP
of HR | 126K | J. Michael Grindel, Ph.D, 54 VP
of Drug Devel. | 208K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|